Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 60

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 60
---
 value that may be realized by the non-employee director. |

| (2) | The aggregate number of shares underlying outstanding options to purchase our Class A common stock held by our non-employee directors as of December 31, 2024 was 639,154, as follows: 74,000 by Dr. Morrissey; 122,893 by Dr. Cheng; 53,850 by Mr. Enright; 63,775 by Ms. Hall; 53,850 by Dr. Katabi; 122,893 by Mr. Morrison; 25,000 by Ms. Oliger; and 122,893 by Dr. Seidenberg. |

| (3) | The amount disclosed represents the aggregate grant date fair value of the RSUs granted in 2024 to Ms. Oliger for consulting services under our 2021 Plan, computed in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the RSUs are set forth in Note 8 to our audited financial statements for the year ended December 31, 2024. This amount does not reflect the actual economic value that may be realized by the non-employee director. |

| (4) | The aggregate number of shares underlying RSUs held by our non-employee directors as of December 31, 2024 was 2,987, all of which were held by Ms. Oliger. |

We have reimbursed and will continue to reimburse all of our non-employee directors for their reasonable out-of-pocket expenses incurred in attending Board and committee meetings. Marshall Fordyce, M.D., our President and Chief Executive Officer, was also a director as of December 31, 2024, but did not receive any additional compensation for his service as a director. See the section titled “Executive Compensation” for more information regarding the compensation earned by Dr. Fordyce.

41

TABLE OF CONTENTS

During the year ended December 31, 2024, each of the following individuals served on our Board as non-employee directors: Michael Morrissey, Ph.D., Andrew Cheng, M.D., Ph.D., Patrick Enright, Kimball Hall, Maha Katabi, Ph.D., Scott Morrison, Christy Oliger and Beth Seidenberg, M.D. Other than as set forth above, none of our non-employee directors earned any compensation in the year ended December 31, 2024 or held any equity awards as of December